Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Thomas Meyers was quoted in the article "Drug-pricing dispute at US Supreme Court raises trade secret disclosure questions," published by MLex [sub. req’d.] on June 24, 2026. The article examines the U.S. Supreme Court’s request for the solicitor general’s views in a challenge to Oregon’s drug-pricing transparency law and the broader implications for constitutional protections of trade secrets and compelled disclosure of confidential business information.

Tom, who leads Sullivan's Life Sciences practice group, discussed the potential consequences of allowing governments to require companies to disclose information they consider proprietary, warning that such requirements could erode longstanding protections for trade secrets. He noted, “I don't think the government, federal or state, should have the right to force disclosure of something that's otherwise regarded as a trade secret. There's a slippery slope here. What are you going to require next?”

He also highlighted the potential impact of varying state disclosure requirements on businesses, adding, “There are other states that have passed similar provisions. We don't really have sufficient guardrails around this... Every state presumably could have a different approach to this, and so companies could be stuck figuring out 50 different strategies.”